Brief: Zynerba Pharmaceuticals Initiates Pivotal Trial Of Zygel In Fragile X Syndrome
13/09/2021 13:51
Sept 13 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS INITIATES RECONNECT, A PIVOTAL
PHASE 3
TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME
* ZYNERBA PHARMACEUTICALS - TOPLINE RESULTS FOR RECONNECT
TRIAL
ARE EXPECTED IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX8nHzZZ
Further company coverage: ZYNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary